HC Wainwright Issues Positive Forecast for LXRX Earnings

Key Points

• HC Wainwright raised its Q3 2026 EPS forecast for Lexicon Pharmaceuticals to a loss of $0.04 per share from $0.05 previously. The firm projects losses of $0.15 per share for fiscal 2026 and $0.20 for fiscal 2027.
• Lexicon’s latest quarterly results missed expectations, with a $0.06-per-share loss versus the $0.05 consensus and revenue of $0.69 million versus estimates of $3.99 million. Revenue fell sharply year over year because the prior period included substantial Novo Nordisk licensing income.
• The company’s pipeline offers potential future catalysts, including completion of enrollment in the Phase 3 SONATA-HCM study and a planned fourth-quarter 2026 resubmission of the ZYNQUISTA application. Lexicon reported $190.6 million in cash and investments, while analysts collectively maintain a “Hold” rating with a $4.55 consensus price target.

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Free Report) - Investment analysts at HC Wainwright raised their Q3 2026 earnings per share estimates for Lexicon Pharmaceuticals in a report issued on Thursday, August 6th. HC Wainwright analyst J. Pantginis now anticipates that the biopharmaceutical company will post earnings of ($0.04) per share for the quarter, up from their prior estimate of ($0.05). The consensus estimate for Lexicon Pharmaceuticals' current full-year earnings is ($0.17) per share. HC Wainwright also issued estimates for Lexicon Pharmaceuticals' Q4 2026 earnings at ($0.03) EPS, FY2026 earnings at ($0.15) EPS and FY2027 earnings at ($0.20) EPS.

Several other research firms also recently commented on LXRX. Wall Street Zen downgraded Lexicon Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Saturday. Weiss Ratings upgraded shares of Lexicon Pharmaceuticals from a "sell (e+)" rating to a "sell (d-)" rating in a report on Thursday, July 23rd. Citigroup upped their price target on shares of Lexicon Pharmaceuticals from $2.30 to $3.10 and gave the stock a "buy" rating in a research report on Monday, May 11th. Finally, Zacks Research cut shares of Lexicon Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Monday, August 3rd. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Lexicon Pharmaceuticals presently has a consensus rating of "Hold" and a consensus target price of $4.55.

Lexicon Pharmaceuticals Price Performance

NASDAQ:LXRX opened at $2.47 on Monday. The firm has a market capitalization of $1.10 billion, a price-to-earnings ratio of -16.47 and a beta of 1.08. Lexicon Pharmaceuticals has a twelve month low of $1.02 and a twelve month high of $2.68. The stock's 50 day moving average price is $2.20 and its two-hundred day moving average price is $1.86. The company has a quick ratio of 13.29, a current ratio of 13.37 and a debt-to-equity ratio of 0.29.

Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.01). The company had revenue of $0.69 million for the quarter, compared to analyst estimates of $3.99 million. Lexicon Pharmaceuticals had a negative net margin of 147.38% and a negative return on equity of 37.53%.

Institutional Trading of Lexicon Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of LXRX. CTC Alternative Strategies Ltd. bought a new position in shares of Lexicon Pharmaceuticals during the 1st quarter worth approximately $27,000. Security National Bank of Sioux City Iowa IA acquired a new stake in Lexicon Pharmaceuticals during the 4th quarter valued at $31,000. Hudson Bay Capital Management LP acquired a new stake in Lexicon Pharmaceuticals during the 2nd quarter valued at $26,000. Bank of New York Mellon Corp lifted its holdings in Lexicon Pharmaceuticals by 43.6% during the 1st quarter. Bank of New York Mellon Corp now owns 27,459 shares of the biopharmaceutical company's stock valued at $43,000 after purchasing an additional 8,335 shares during the last quarter. Finally, Leonteq Securities AG bought a new position in Lexicon Pharmaceuticals during the fourth quarter worth $34,000. Institutional investors own 74.70% of the company's stock.

Key Lexicon Pharmaceuticals News

Here are the key news stories impacting Lexicon Pharmaceuticals this week:

• Positive Sentiment: Lexicon completed enrollment in the pivotal Phase 3 SONATA-HCM study of sotagliflozin for hypertrophic cardiomyopathy, exceeding its 500-patient enrollment target. Top-line results remain expected in the first quarter of 2027, providing a potentially significant future catalyst. Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates
• Positive Sentiment: The company said its activities to resubmit the ZYNQUISTA NDA for glycemic control in adults with type 1 diabetes are nearing completion, with resubmission anticipated in the fourth quarter of 2026. Phase 1 development of obesity candidate LX9851 is also continuing through partner Novo Nordisk, and Lexicon could receive an additional $10 million milestone payment as early as later this year. Lexicon Pharmaceuticals Q2 2026 Earnings Call Transcript
• Positive Sentiment: Lexicon reported $190.6 million in cash and investments at June 30, supported by $96.2 million in stock-sale proceeds, giving it additional resources to fund clinical development. A Hercules Capital facility also provides up to $100 million in potential financing, subject to conditions.
• Neutral Sentiment: Management emphasized disciplined capital allocation and early commercial planning for its late-stage pipeline. However, the principal value drivers remain dependent on successful clinical results and regulatory approval.
• Negative Sentiment: Second-quarter revenue fell to approximately $0.7 million from $28.9 million a year earlier because the prior-year period included substantial Novo Nordisk licensing revenue. The company posted a net loss of roughly $31.8 million, or $0.07 per share, versus net income of $3.3 million in the prior-year quarter. Revenue also came in below analyst expectations, while research and development spending rose to $17.4 million as SONATA-HCM costs increased. Lexicon Pharmaceuticals Reports Q2 Loss, Lags Revenue Estimates

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon's approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases.

The company's most advanced product is telotristat ethyl (sold under the brand name XERMELO), an oral treatment approved for the management of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source